Drugs / R21 Matrix-M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06879327 | May 2025 → Oct 2027 expected | Plasmodium falciparum malaria | PATH | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R21 Matrix-M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879327 ↗ |
| Known as | R21/MM | “R21 Matrix-M (R21/MM) Malaria Vaccine” NCT06879327 ↗ |
| Modality | Vaccine | “R21/MM malaria vaccine” NCT06879327 ↗ |
| Route | Intramuscular | “Administered by intramuscular injection.” NCT06879327 ↗ |